OmegaChem
Sygnature Discovery is a UK- and Canada-headquartered contract research organization with 700+ scientists delivering integrated drug discovery services — from target identification through pre-clinical development — to biotech and pharmaceutical companies across multiple therapeutic areas and modalities.
- Company typePrivate
- Founded1988
- HeadquartersLévis, Canada
- Headcount101–250
- GTM typeB2B
- OfferingServices
What OmegaChem does
The company operates as an integrated contract research organization (CRO) providing drug discovery services from target identification through pre-clinical development, with 700+ scientists located across Europe (Nottingham UK headquarters at BioCity) and North America (Montreal, Quebec through the integrated NuChem Sciences entity). Operations span all major preclinical disciplines: computer-aided drug design, protein science and structural biology (including cryo-EM, NMR, and X-ray crystallography), bioscience, medicinal and synthetic chemistry, DMPK, in vivo pharmacology, and formulation. The service portfolio covers both fully integrated multi-year discovery programs and standalone project support, addressing biotech clients from early-stage startups to large pharmaceutical companies.
The technology stack combines proprietary platforms — SygDesign (informatics for library design), CHARMED (targeted protein degradation enabling work on previously 'undruggable' targets), and Direct-to-Biology (compressed hit-to-candidate workflow) — with AI/ML capabilities including generative AI for de novo molecular design (delivered via Iktos Makya), ADMET prediction, virtual screening, and AI-augmented target identification. The company supports multiple modalities: small molecules, peptides, targeted protein degradation, antibody-drug conjugates, and biologics. A strategic collaboration with DaltonTx extends AI capability development.
The business model is fee-for-service contract research, with projects ranging from targeted single-discipline engagements to fully integrated discovery programs. Pricing is project-based and not publicly disclosed, structured around multi-year contracts. Customers are primarily biotech and pharmaceutical companies in oncology, neuroscience, immunology, inflammation, and metabolic disease, including named engagements with STORM Therapeutics (DHX9 inhibitor, lead-to-pre-candidate in 18 months), CellCentric (Inobrodib, in Phase I/II), Corcept Therapeutics (cortisol regulation candidate), and Sitryx (immunology/inflammation). Track record includes 60+ advanced candidates since 2011 (23 preclinical, 36 clinical, 2 FDA-approved), 200+ patents filed, and a stated 90%+ customer retention rate.
OmegaChem firmographics
Firmographics- Name
- OmegaChem
- Website
- https://omegachem.com
- Company type
- Private
- Founded year
- 1988
- Headcount range
- 101–250 employees
- Short description
- Sygnature Discovery is a UK- and Canada-headquartered contract research organization with 700+ scientists delivering integrated drug discovery services — from target identification through pre-clinical development — to biotech and pharmaceutical companies across multiple therapeutic areas and modalities.
- Ownership category
- akta.pro rank
OmegaChem industry classification
Industry- Product category
- Contract Research / Drug Discovery Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where OmegaChem is headquartered
LocationHeadquarters
- HQ city
- Lévis
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
OmegaChem business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: Fee-for-service contract research organization providing drug discovery services on a project basis. Services range from targeted project support to fully integrated discovery programs. Revenue generated through scientific solution provision across all preclinical discovery stages.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based contract research services |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
OmegaChem product offering
Product offeringCore offering
OmegaChem operates as a contract research organization (CRO) providing integrated drug discovery services to biotechnology and pharmaceutical companies. Services span from target identification and validation through hit identification, hit-to-lead, lead optimization, and pre-clinical candidate nomination across multiple modalities including small molecules, peptides, targeted protein degradation, ADCs, and biologics. The offering combines AI-enabled drug design, proprietary informatics (SygDesign), and multidisciplinary scientific expertise delivered as fully integrated programs or standalone scientific solutions.
Product overview
Sygnature Discovery is a contract research organization (CRO) providing integrated drug discovery services through a platform-plus-expertise model. The core offering centers on fully integrated drug discovery programs supported by specialized scientific solution modules including Computer Aided Drug Design (CADD), Protein Science and Structural Biology, Bioscience, Chemistry, DMPK, in vivo Pharmacology, and Form & Formulation. The company also offers modality-specific expertise (Small Molecules, Peptides, Targeted Protein Degradation, ADCs, Biologics) and proprietary informatics tools like SygDesign. Services span from target identification through pre-clinical development, with AI and automation powering workflows across all disciplines.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- 60+ advanced candidates since 2011 (23 preclinical, 36 clinical, 2 approved)
- +3 more outcomes
Companies that use OmegaChem
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
OmegaChem technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature4 records
OmegaChem partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- DaltonTxcoreStrategic collaboration with AI technology company DaltonTx to advance AI-enabled drug discovery capabilities. Partnership aims to further enhance Sygnature Discovery's integrated drug discovery platform with advanced AI technologies.
- IktoscoreCollaboration using Iktos Makya generative AI platform for de novo molecular design. Rapid creation of ideas using generative AI algorithms enabling rapid idea generation to address medicinal chemistry project objectives.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
OmegaChem competitors and assessment
Company assessmentEmerging players
- GenScript Biotech: Biologics-focused CRO with growing integrated discovery and preclinical capabilities across peptides, proteins, and cell therapy; comparable in modality breadth (biologics, peptides) and customer overlap.
- Schrödinger, Inc. AI-native computational drug discovery platform with in-house pipeline and software licensing; not a full-service CRO but targets the same CADD/AI-enabled discovery workflows and increasingly competes for biotech discovery budgets.
- Insilico Medicine: AI-native drug discovery company with proprietary generative chemistry and biology platforms plus an internal pipeline; overlaps with AI/ML-driven discovery workflows the firm is investing in.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning; competing for early discovery attention and partnerships in the same biotech customer segment.
Direct peers
- Pharmaron: China-headquartered CRO providing integrated drug discovery and development services (chemistry, DMPK, biology, in vivo pharmacology) to biotech and pharma; directly comparable service stack and customer base.
- Evotec SE: Hamburg-based integrated drug discovery CRO offering target ID through preclinical services across small molecules and biologics; competes directly with the firm's full-service discovery model and shares the no-internal-pipeline, fee-for-service positioning.
Broad incumbents
- Eurofins Discovery: Part of Eurofins Scientific, offering integrated discovery services (medicinal chemistry, in vitro pharmacology, ADME) to pharma and biotech; broader portfolio but direct overlap in discovery services.
- WuXi AppTec: Global CRO/CDMO with extensive discovery services (WuXi Biology, WuXi Chemistry) across small molecules and biologics; broader scale and geographic reach but overlapping integrated discovery offering.
- Labcorp Drug Development (Fortrea): Spin-off from Labcorp providing clinical and preclinical drug development services; larger and more clinical-focused but competes for integrated discovery and early development work.
- Charles River Laboratories: Large, publicly traded CRO with end-to-end discovery, preclinical, and clinical capabilities; broader portfolio but significant overlap in medicinal chemistry, DMPK, and in vivo pharmacology services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
OmegaChem social profiles
Digital presenceOmegaChem financial estimates
Financial estimateRevenue estimate
Valuation estimate
OmegaChem leadership team
Management profileNumber of profiles
Profiles2 records
OmegaChem funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OmegaChem M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OmegaChem
What does OmegaChem do?
OmegaChem operates as a contract research organization (CRO) providing integrated drug discovery services to biotechnology and pharmaceutical companies. Services span from target identification and validation through hit identification, hit-to-lead, lead optimization, and pre-clinical candidate nomination across multiple modalities including small molecules, peptides, targeted protein degradation, ADCs, and biologics. The offering combines AI-enabled drug design, proprietary informatics (SygDesign), and multidisciplinary scientific expertise delivered as fully integrated programs or standalone scientific solutions.
When was OmegaChem founded?
OmegaChem was founded in 1988. It employs 101 to 250 people.
Where is OmegaChem based?
OmegaChem is headquartered in Lévis, Canada, in the North America region.
How does OmegaChem make money?
One revenue line is on record: contract Research Services.
Who are OmegaChem's main competitors?
Emerging players on record are GenScript Biotech, Schrödinger, Inc., Insilico Medicine and Recursion Pharmaceuticals. Direct peers are Pharmaron and Evotec SE. Broad incumbents are Eurofins Discovery, WuXi AppTec, Labcorp Drug Development (Fortrea) and Charles River Laboratories.
Does OmegaChem have an API?
No public API is recorded for OmegaChem.
What industry is OmegaChem in?
OmegaChem's product category is Contract Research / Drug Discovery Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 5417 and its SIC code is 8731.